# Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

> **NCT06760156** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 28 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **DRUG:** Tafasitamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06760156
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-19
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06760156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06760156, "Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06760156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*